Singapore-based medtech firm Curiox Biosystems has raised US$15 million in funding from Korean biotech investors.
The deal is backed by KB Investment, IMM Investment, Quad Investment, HB Investment, Dayli Investment, and SV Investment.
Curiox is a spinoff company from the Agency for Science, Technology, and Research under the Ministry of Trade and Industry of Singapore. It develops bio instrumentation solutions for use in cell analysis and therapy in the pharmaceutical and biotech industries.
The company now plans to use the investment to scale up and accelerate its commercialization activities globally. It said it has successfully penetrated markets in the US, China, Korea, and Europe.